Nemaura also continues to support its UK licensee with its application for reimbursement of sugarBEAT in the UK
Nemaura Medical secures $6.5m in non-dilutive funding. (Credit: Photo Mix from Pixabay)
Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces that it has secured a further $6.5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements, from its existing lender.
In July 2023 Nemaura exhibited and undertook product demonstrations at the American Diabetes Association meeting in San Diego, the world’s largest gathering of Diabetes professionals, where it received very encouraging feedback from dialogue with attendees including corporates, Diabetes service providers and clinicians, which it continues to follow up on. The company is also currently undertaking studies with the NHS (National Health Service) in the UK with its metabolic health program designed for the consumer market targeting obesity and pre-diabetes whilst refining its commercial offering in this space. Nemaura also continues to support its UK licensee with its application for reimbursement of sugarBEAT in the UK.
Source: Company Press Release